Carney complex
Autosomal dominant multi-organ tumor syndrome (historically LAMB / NAME syndrome): ~70% germline PRKAR1A on 17q24 encoding PKA regulatory subunit 1α; ~30% PRKACA or other causes; rare familial PRKAR1B. Loss of PKA-R1α function dysregulates cAMP-PKA signaling and produces a characteristic constellation of endocrine and non-endocrine neoplasia plus pigmentary lesions. Stratakis criteria 2001/2021: 2 of 12 major features, OR 1 major + germline PRKAR1A, OR 1 major + first-degree CNC relative. The 12 major features: SPOTTY SKIN PIGMENTATION (lentigines + blue nevi, characteristically on face + lips + conjunctiva + sclera); PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DISEASE (PPNAD) causing ACTH-INDEPENDENT CUSHING'S SYNDROME in ~25-50% of patients (atypical presentation often cyclical or paradoxically increasing on Liddle's test rather than dexamethasone-suppressed); CARDIAC MYXOMAS in ~30-60% (ANY chamber + ANY age + often multiple + recurrent — MAJOR MORTALITY DRIVER from embolic stroke + intracardiac obstruction + sudden death); cutaneous myxomas (eyelids + ears + nipple + extremities); mammary myxoid fibroadenomas; LARGE CELL CALCIFYING SERTOLI CELL TUMORS (LCCSCT) in ~30-40% of males (bilateral, mostly benign, estrogen-secreting → gynecomastia + precocious puberty); GH-SECRETING PITUITARY ADENOMA in ~10-15% → acromegaly; thyroid nodules + thyroid carcinoma (papillary, follicular); psammomatous melanotic schwannoma (characteristic CNC tumor); osteochondromyxoma (rare). Surveillance per Stratakis + Carney Complex Foundation, LIFELONG and multi-organ: annual ECHOCARDIOGRAM (atrial AND ventricular AND multiple foci — aggressive resection at detection given recurrence risk); urinary free cortisol + LDDST every 6-12 months from childhood; testicular ultrasound annually from age 5; thyroid ultrasound annually; IGF-1 + GH annually from puberty; neurologic-complaint imaging (melanotic schwannoma); cutaneous exam. Management: aggressive cardiac myxoma resection at detection (single most important intervention); bilateral adrenalectomy for PPNAD-driven Cushing's (cortisol replacement lifelong); orchiectomy / testicular-sparing surgery for LCCSCT; transsphenoidal surgery + SSAs + GH receptor antagonists for acromegaly; thyroid surgery. Mortality dominated by cardiac myxoma complications. Carney Complex Foundation patient advocacy; Stratakis NIH group reference center; Endocrine Society + ESE. **Editorial**: GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) TIER 2 MECHANISTICALLY CONTRAINDICATED — GHRH-receptor signaling activates Gs / cAMP / PKA, the EXACT pathway PRKAR1A loss-of-function constitutively dysregulates. Three independent vectors stack: (1) tesamorelin FDA label contraindicates pituitary tumor history; (2) ~10-15% CNC baseline GH-secreting adenoma risk; (3) upstream stimulus on already-dysregulated pathway. BPC-157 pro-angiogenic overlaps cardiac myxoma surveillance. NMN general-aging doesn't engage PRKAR1A. Fifty-ninth deliberate non-elevation.
What changes during this transition
Carney complex (CNC, historically LAMB / NAME syndrome) is an autosomal dominant multiple-tumor syndrome — ~70% of cases driven by germline pathogenic variants in PRKAR1A on 17q24 (encoding the regulatory subunit type 1α of protein kinase A), with ~30% carrying PRKACA mutations or other genetic causes and rare familial CNC with PRKAR1B variants. Loss of PKA-R1α function dysregulates cAMP-PKA signaling and produces a characteristic constellation of endocrine and non-endocrine neoplasia plus pigmentary lesions. Diagnosis follows the Stratakis criteria (2001 / updated 2021): 2 of 12 major features, or 1 major feature + germline PRKAR1A mutation, or 1 major feature + an affected first-degree relative. The 12 major features include: spotty skin pigmentation (lentigines + blue nevi, characteristically on face, lips, conjunctiva, and sclera); primary pigmented nodular adrenocortical disease (PPNAD) causing ACTH-independent Cushing's syndrome in ~25–50% of patients — often presenting atypically in young adults, sometimes cyclical, sometimes with a paradoxical Liddle's-test increase rather than dexamethasone suppression; cardiac myxomas in ~30–60% (any chamber, any age, often multiple and recurrent — the dominant mortality driver via embolic stroke, intracardiac obstruction, and sudden death); cutaneous myxomas (eyelids, ears, nipple, extremities); mammary myxoid fibroadenomas; large cell calcifying Sertoli cell tumors (LCCSCT) in ~30–40% of male patients (bilateral, mostly benign but estrogen-secreting → gynecomastia, precocious puberty); GH-secreting pituitary adenoma in ~10–15% causing acromegaly; thyroid nodules and thyroid carcinoma (papillary, follicular); psammomatous melanotic schwannoma (characteristic CNC tumor, any nerve root); and osteochondromyxoma (rare bone tumor). Pediatric presentations skew toward cardiac myxomas + LCCSCT + spotty pigmentation; adult presentations skew toward cardiac myxomas + PPNAD + acromegaly. Surveillance per Stratakis and the Carney Complex Foundation is lifelong and multi-organ: annual echocardiogram (atrial AND ventricular, multiple foci possible — aggressive resection at detection is the single most important intervention given recurrence risk); urinary free cortisol + LDDST every 6–12 months from childhood; testicular ultrasound annually from age 5; thyroid ultrasound annually; IGF-1 + GH annually from puberty; imaging for any neurologic complaint; routine cutaneous exam. Management is multi-organ + lifelong: aggressive cardiac myxoma resection at detection, bilateral adrenalectomy with lifelong cortisol replacement for PPNAD-driven Cushing's, orchiectomy or testicular-sparing surgery for symptomatic / growing LCCSCT, transsphenoidal surgery + somatostatin analogs + GH receptor antagonists for acromegaly, thyroid surgery for malignant nodules. Mortality is dominated by cardiac myxoma complications. From a peptide-substrate perspective: the load-bearing concern is cAMP-PKA pathway dysregulation. GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) are the sharpest concern — GHRH-receptor signaling activates Gs / cAMP / PKA, which is the exact pathway PRKAR1A loss-of-function constitutively dysregulates; ~10–15% of CNC patients carry a GH-secreting adenoma surveillance line; tesamorelin's FDA label explicitly contraindicates pituitary tumor history. Pro-angiogenic peptides (BPC-157) overlap with cardiac myxoma surveillance concerns. General-aging supplements (NMN) don't engage PRKAR1A biology but the 'healthspan' framing isn't load-bearing in a patient whose trajectory is dominated by multi-organ tumor surveillance. The dominant intervention is the CNC endocrinology + cardiology surveillance program (Stratakis-network or equivalent), not peptides — family-screening obligations, lifelong monitoring from childhood, and the psychological weight of multi-organ surveillance are real, and any peptide conversation belongs inside the syndrome-aware care team, not parallel to it. Juno's CNC substrate is editorial / honest-answer infrastructure for the /ask surface; this is the 59th deliberate non-elevation — no peptides are surfaced as discovery cards on this hub.
Important caveat
CNC is managed by multidisciplinary endocrinology + cardiology + (depending on manifestations) endocrine surgery + neurosurgery + dermatology — typically Stratakis-network-aligned centers. **CHILDHOOD-ONSET SURVEILLANCE BURDEN**: testicular ultrasound from age 5; UFC + LDDST every 6-12 months from childhood; IGF-1 + GH annually from puberty; thyroid ultrasound annually; annual echocardiogram lifelong. **CARDIAC MYXOMAS ARE THE DOMINANT MORTALITY DRIVER**: any chamber + any age + multiple + recurrent; aggressive resection at detection is the single most important intervention; new neurologic deficit + syncope + heart failure / arrhythmia symptoms in CNC = urgent cardiology evaluation (embolic stroke + intracardiac obstruction + sudden death). **PPNAD CUSHING'S IS ATYPICAL**: often cyclical; paradoxical Liddle's-test increase rather than dexamethasone suppression is characteristic; ACTH-independent; bilateral adrenalectomy is definitive; lifelong cortisol replacement after. **GH-AXIS PEPTIDES (CJC-1295, tesamorelin, ipamorelin, sermorelin, MK-677) ARE TIER 2 MECHANISTICALLY CONTRAINDICATED**: three independent vectors stack — (1) tesamorelin FDA label contraindicates pituitary tumor history; (2) ~10-15% CNC baseline GH-secreting adenoma rate with standing IGF-1 + GH surveillance from puberty; (3) GHRH-receptor signaling activates Gs / cAMP / PKA, the EXACT pathway PRKAR1A loss-of-function constitutively dysregulates. Treat the entire GH-axis class as one decision and recognize it is mechanistically contraindicated outside a CNC-aware endocrinology framework that has actively considered and excluded somatotroph involvement. **BPC-157**: pro-angiogenic VEGF / eNOS signaling overlaps cardiac myxoma surveillance and multi-organ tumor diathesis; no CNC characterization; the injury-recovery framing is not load-bearing enough to override syndrome-level risk. **NMN**: general-aging healthspan framing doesn't engage PRKAR1A / PKA biology; surveillance program owns the health trajectory, not NAD+ levels. **LCCSCT IN MALES** (~30-40%): estrogen-secreting → gynecomastia + precocious puberty in pediatric patients; mostly benign but require surveillance and surgical intervention if growing / symptomatic. **MELANOTIC SCHWANNOMA**: characteristic CNC tumor that can present at any nerve root; new neurologic complaint warrants imaging. **FAMILY SCREENING**: cascade genetic testing of first-degree relatives is part of the care model; PRKAR1A testing definitive. Carney Complex Foundation + AMEND patient advocacy; Stratakis NIH group is the primary clinical reference. WADA athletes: peptide GH secretagogues prohibited at all times. Pregnancy in CNC is high-risk; coordinate endocrinology + cardiology + maternal-fetal medicine.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.